IP Library › Granted Patent US 12,612,455
Granted Patent B2
US 12,612,455 · App. 18/246,725 · Granted Apr 28, 2026

Feline antibody variants

Inventors: Lisa Marie Bergeron (Boulder, CO); Henry Luis Campos (Kalamazoo, MI)
Assignee: Zoetis Services LLC
C07K16/22C07K16/00C07K16/18C07K2317/20C07K2317/52C07K2317/524C07K2317/526C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,612,455
App. No.
18/246,725
Granted
Apr 28, 2026
Kind
B2
Abstract

The invention relates generally to feline antibody variants and uses thereof. Specifically, the invention relates to mutations in the constant region of feline antibody for improving its half-life and other characters.

Claims (19)

1 . A modified IgG comprising:

a feline IgG constant domain comprising at least one amino acid substitution relative to a wild-type feline IgG constant domain, wherein said substitution is at amino acid residue 434, numbered according to the EU index as in Kabat,

wherein said substitution is a substitution of serine at position 434 with histidine (S434H),

wherein said IgG is an anti-TGFβ molecule, and

wherein the anti-TGFβ molecule comprises a variable heavy (VH) chain having the amino acid sequence set forth in SEQ ID NO.: 45, 55, 65, 75, 85, 95, 105, 115, 125, or 135 and a variable light (VL) chain having the amino acid sequence set forth in SEQ ID NO.: 47, 57, 67, 77, 87, 97, 107, 117, 127, or 137.

2 . The modified IgG of claim 1 , wherein said feline IgG constant domain comprises another substitution, wherein said another substitution is at amino acid residue 428.

3 . The modified IgG of claim 2 , wherein said another substitution is a substitution of serine at position 428 with leucine (S428L).

4 . The modified IgG of claim 1 , wherein the modified IgG has a higher affinity for FcRn than an IgG having the wild-type feline IgG constant domain.

5 . The modified IgG of claim 1 , wherein the modified IgG has a higher half-life than an IgG having the wild-type feline IgG constant domain.

6 . The modified IgG of claim 1 , wherein the modified IgG comprises an Fc constant region having CH2 or CH3 domain, or a combination thereof.

7 . The modified IgG of claim 1 , wherein the wild-type feline IgG constant domain comprises the amino acid sequence set forth in SEQ ID NO.: 3.

8 . A pharmaceutical composition comprising the modified IgG of claim 1 and a pharmaceutically acceptable carrier.

9 . A kit comprising the modified IgG of claim 1 , in a container, and instructions for use.

10 . A fusion molecule comprising the modified IgG of claim 1 .

11 . A method for increasing the serum half-life of a feline IgG molecule in a cat, the method comprising: administering said cat a composition comprising a modified IgG, said modified IgG comprising a feline IgG constant domain, said feline IgG constant domain comprising at least one amino acid substitution relative to a wild-type feline IgG constant domain, wherein said substitution is at amino acid residue 434, numbered according to the EU index as in Kabat, wherein said substitution is a substitution of serine at position 434 with histidine (S434H), wherein said IgG is an anti-TGFβ molecule, and wherein the anti-TGFβ molecule comprises a variable heavy (VH) chain having the amino acid sequence set forth in SEQ ID NO.: 45, 55, 65, 75, 85, 95, 105, 115, 125, or 135 and a variable light (VL) chain having the amino acid sequence set forth in SEQ ID NO.: 47, 57, 67, 77, 87, 97, 107, 117, 127, or 137.

12 . The method of claim 11 , wherein said feline IgG constant domain further comprising a substitution at amino acid residue 428, numbered according to the EU index as in Kabat.

13 . The method of claim 12 , wherein said substitution is a substitution of serine at position 428 with leucine (S428L).

14 . The method of claim 11 , wherein the modified IgG comprises an Fc constant region having CH2 or CH3 domain, or a combination thereof.

15 . The method of claim 11 , wherein the wild-type feline IgG constant domain comprises the amino acid sequence set forth in SEQ ID NO.: 3.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2023
From: BERGERON, LISA MARIE; CAMPOS, HENRY LUIS
To: ZOETIS SERVICES LLC
Reel/Frame 065975/0001 →
Continuity (2)
Provisional Application 63084693 · Sep 29, 2020
Related Publication 20230382986A1 · Nov 30, 2023
References Cited (66)
US 4816397A · Boss et al. · 1989 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5698762A · Dauerman · 1997 [cited by applicant]
US 5807715A · Morrison et al. · 1998 [cited by applicant]
US 6284471B1 · Le et al. · 2001 [cited by applicant]
US 8012482B2 · Adams et al. · 2011 [cited by applicant]
US 8088376B2 · Chamberlain et al. · 2012 [cited by applicant]
US 8394925B2 · Chamberlain et al. · 2013 [cited by applicant]
US 8546543B2 · Lazar · 2013 [cited by applicant]
US 8790651B2 · Bammert et al. · 2014 [cited by applicant]
US 9206253B2 · Bammert et al. · 2015 [cited by applicant]
US 9505829B2 · Lacy et al. · 2016 [cited by applicant]
US 9617334B2 · Bergeron et al. · 2017 [cited by applicant]
US 9803023B2 · Chamberlain et al. · 2017 [cited by applicant]
US 9951128B2 · Bergeron et al. · 2018 [cited by applicant]
US 10093725B2 · Lacy et al. · 2018 [cited by applicant]
US 10125192B2 · Lacy et al. · 2018 [cited by applicant]
US 10336818B2 · Chamberlain et al. · 2019 [cited by applicant]
US 10421807B2 · Gonzales et al. · 2019 [cited by applicant]
US 10526405B2 · Mann et al. · 2020 [cited by applicant]
US 20030031671A1 · Welt et al. · 2003 [cited by applicant]
US 20060067930A1 · Adams et al. · 2006 [cited by applicant]
US 20220048981A1 · Nakao et al. · 2022 [cited by applicant]
WO 1986001533A1 · 1986 [cited by applicant]
WO 2019113123A1 · 2019 [cited by applicant]
WO 2020082048A1 · 2020 [cited by applicant]
WO 2021212084A1 · 2021 [cited by applicant]
WO 2022072446A1 · 2022 [cited by applicant]
WO 2022133252A1 · 2022 [cited by applicant]
Bird R.E., et al., Science, 1988, vol. 240, pp. 423-426. [cited by applicant]
Bowie J.U., et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science, 1990, vol. 247, pp. 1306-1310. [cited by applicant]
Buhren J., et al., “Optical Effects of Anti-TGFBeta Treatment after Photorefractive Keratectomy in a Cat Model,” Investigative Ophthalmology and Visual Science, Feb. 1, 2009, vol. 50, No. 2, pp. 634-643, doi: 10.1167/io… [cited by applicant]
Burmeister W.P., et al., “Crystal Structure of the Complex of Rat Neonatal Fc Receptor with Fc”, Letters Of Nature, Nov. 24, 1994, vol. 372, No. 6504, pp. 379-383, doi: 10.1038/372379a0. [cited by applicant]
Cunningham B.C., et al., “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis”, Science, Jun. 2, 1989, vol. 244, pp. 1081-1085. [cited by applicant]
De Vos A.M., et al., “Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex”, Science, 1992, vol. 255, pp. 306-312. [cited by applicant]
Ellman., et al., Methods in Enzymology, 1991, vol. 202, pp. 301-336. [cited by applicant]
Gorman M.C., et al., “The Rous Sarcoma Virus Long Terminal Repeat is a Strong Promoter When Introduced into a Variety of Eukaryotic cells by DNA-mediated Transfection”, Proceedings of the National Academy of Sciences, U… [cited by applicant]
Grosschedi R., et al., “Cell-Type Specificity of Immunoglobulin Gene Expression is Regulated by at Least Three DNA Sequence Elements,” Cell, Jul. 1985, vol. 41, pp. 885-897(13 Pages). [cited by applicant]
Guyer R.L., et al., “Immunoglobulin Binding by Mouse Intestinal Epithelial Cell Receptors”, Journal of Immunology, vol. 117, No. 2, 1976, pp. 587-593. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2021/052579, dated Apr. 13, 2023, 11 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/052579, dated Mar. 15, 2022, 18 Pages. [cited by applicant]
Izaki, Japanese Journal of Bacteriology, 1978, vol. 33, pp. 729-742. [cited by applicant]
John J.F., et al., “Plasmids as Epidemiologic Markers in Nosocomial Gram-Negative Bacilli: Experience at a University and Review of the Literature”, Reviews of Infectious Diseases, 1986, vol. 8, No. 5, pp. 693-704. [cited by applicant]
Kendall, et al., Journal of Bacteriology, 1987, vol. 169, pp. 4177-4183. [cited by applicant]
Kim J-K., et al., “Localization of the Site of the Murine IgG1 Molecule that is Involved in Binding to the Murine Intestinal Fc Receptor,” The European Journal of Immunology, 1994, vol. 24, pp. 2429-2434. [cited by applicant]
Lathe R., “Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data: Theoretical and Practical Considerations”, Journal of Molecular Biology, vol. 183, 1985, pp. 1-12. [cited by applicant]
Lawson U.S., et al., “Characterisation of Feline Renal Cortical Fibroblast Cultures and Their Transcriptional Response to Transforming Growth Factor Beta1”, BMC Veterinary Research, Mar. 9, 2018, vol. 14, No. 1, 76, Ret… [cited by applicant]
Lawson U.S., et al., “The Cat as a Naturally Occurring Model of Renal Interstitial Fibrosis: Characterisation of Primary Feline Proximal Tubular Epithelial Cells and Comparative Pro-Fibrotic Effects of TGF-[beta]1,” Plo… [cited by applicant]
Newman R., et al., Biotechnology, 1993, vol. 10, pp. 1455-1460. [cited by applicant]
Oganesyan V., et al., “Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms”, Journal of Biological Chemistry, Mar. 14, 2014, vol. 289, No. 11, pp. 7812-7824, doi:10.1074/jbc.M113.537563. [cited by applicant]
Okayama H., et al., “A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells”, Molecular and Cellular Biology, Feb. 1983, vol. 3, No. 2, pp. 280-312. [cited by applicant]
Pearson W.R., et al., “Improved Tools for Biological Sequence Comparison”, Proceedings of the National Academy of Sciences of the United States of America, Apr. 1988, vol. 85, pp. 2444-2448. [cited by applicant]
Perez J.M., et al., “Critical Approach to the Alternative Treatment of Chronic Kidney Disease in Dogs and Cats”, Slovenian Veterinary Research, Jul. 23, 2018, vol. 55, No. 2, pp. 59-71, DOI: 10.26873/SVR-273-2017, ISSN … [cited by applicant]
Pluckthunkerra , Methods in Enzymology, 1989, vol. 178, pp. 497-515. [cited by applicant]
Rattan S.I., et al., “Protein Synthesis, Posttranslational Modifications, and Aging”, Annals of the New York Academy of Sciences, 1992, vol. 663, pp. 48-62. [cited by applicant]
Saxena A., et al., “Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life”, Frontiers Immunology, Dec. 12, 2016, Sec. Vaccines and Molecular Therapeutics, vol. 7, R… [cited by applicant]
Seifter S., et al., “Analysis for Protein Modifications and Nonprotein Cofactors”, Methods in Enzymology, 1990, vol. 182, pp. 626-646. [cited by applicant]
Shields R.L., et al., “High Resolution Mapping of the Binding Site on Human IgG1 for Fc Gamma RI, Fc Gamma RII, Fc Gamma RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc Gamma R”, Journal of Bi… [cited by applicant]
Smith L.J., et al., “Human Interlukin 4 The Solution Structure of a Four-Helix Bundle Protein”, Journal of Molecular Biology, 1992, vol. 224, pp. 899-904. [cited by applicant]
Strietzel C.J., et al., “In Vitro Functional Characterization of Feline IgGs”, Veterinary Immunology and Immunopathology, Apr. 15, 2014, vol. 158, No. 3, pp. 214-223, Retrieved from http://dx.doi.org/10.1016/j.vetimm.20… [cited by applicant]
“TGF-beta 1, 2, 3 Antibody”, Catalog #MAB1835, Monoclonal Mouse IgG1 Clone #1D11, R&D Systems, Retrieved from https://www.rndsystems.com/products/tgf-beta1-2-3-antibody-1d11_mab1835. [cited by applicant]
Weidle U.H., et al., “Reconstitution of Functionally Active Antibody Directed Against Creatine Kinase from Separately Expressed Heavy and Light Chains in Non-lymphoid Cells”, Gene, 1987, vol. 51, pp. 21-29. [cited by applicant]
Whittle, et al., Protein Engineering, 1987, vol. 1, p. 499. [cited by applicant]